Print this page
-
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Applicable Disease Sites: Lip, Oral Cavity and Pharynx
-
A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-Line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Protocol: 032409Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/ Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients.
Protocol: 032410Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Pilot Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy (PORT) for Minimal Residual Disease (MRD) for Lung Cancer: the MRD-PORT Trial.
Protocol: 032411Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
Protocol: 032501Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab
Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small
Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1
Expression
Protocol: 032502Principal Investigator:
- Sivraj Muralikrishnan
Applicable Disease Sites: Lung -
Remote Bimanual Virtual Rehabilitation for Elderly with Cerebral Vascular Disease
Protocol: 042014Principal Investigator:
- Jasdeep S Hundal
Applicable Disease Sites: Brain and Nervous System -
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy.
Protocol: 042201Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer.
Protocol: 042208Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
Pilot Study to Investigate the Metabolic Pathways in Hormone Receptor-Positive/HER2-Negative Breast Cancer.
Protocol: 042210Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.
Protocol: 042211Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-Stage Triple-Negative Breast Cancer.
Protocol: 042304Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE).
Protocol: 042305Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
RADIANT Study: Phase Ib Study of Pre-op Radiation with Abemaciclib and Letrozole in Early Stage Breast Cancer.
Protocol: 042311Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast